Cabozantinib,Nivolumab,Ipilimumab
Exelixis,bms
['nivo', 'triplet,(-triplete)', 'rcc,(-irccs),(-srcc),(-urcc)', 'cosmic-313', ' ipi ', ' cabo ']
cosmic-313: cabo + nivo + ipi vs placebo + nivo + ipi in untreated intermediate/poor risk advanced rcc prolongs pfs (nr vs 11.3 months, hr 0.73) at the cost of increased toxicity (grade 3/4 traes 73% vs 41%, same % of grade 5). given os benefit, who will need a triplet? #esmo2022
28. MD. PhD student. Medical Oncology trainee at Ramón y Cajal University Hospital (Madrid). ES ????| EN ????| FR ????| ZH ????| ???? ??Avid traveller! ????